Skip to content

Study · Animal study (in vivo) · rat · 2011

4 results

[Effect of GB-115 dipeptide on anxiety in rats with model benzodiazepine withdrawal syndrome].

Kolik LG, Kadnikov IA, Zhukov VN, Gudasheva TA, Seredenin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2011

PMID22238979 (opens in a new tab)PepBankPUB-22238979
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats after benzodiazepine withdrawal, GB‑115 increased stay time in the elevated plus maze.

    In plain wordsIn rats after benzodiazepine withdrawal, GB‑115 increased maze stay time.

    Peptide
    GB-115
    Outcome
    IncreaseElevated plus maze stay time
    Study

    ratn: not reported in source

    Benzodiazepine withdrawal
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.1 and 0.5 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    It is established that, in 24-48 h following BZ withdrawal, GB-115 dipeptide administered in doses of 0.1 and 0.5 mg/kg, i.p., produced an anxiolytic effect in all animals, which was manifested by increasing the stay time and number of entries in EPM.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats after benzodiazepine withdrawal, GB‑115 increased the number of elevated plus maze entries.

    In plain wordsIn rats after benzodiazepine withdrawal, GB‑115 increased maze entries.

    Peptide
    GB-115
    Outcome
    IncreaseElevated plus maze entries
    Study

    ratn: not reported in source

    Benzodiazepine withdrawal
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    0.1 and 0.5 mg/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    It is established that, in 24-48 h following BZ withdrawal, GB-115 dipeptide administered in doses of 0.1 and 0.5 mg/kg, i.p., produced an anxiolytic effect in all animals, which was manifested by increasing the stay time and number of entries in EPM.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In outbred rats during diazepam withdrawal, GB‑115 increased striatal DOPAC levels by 25%.

    In plain wordsIn rats during diazepam withdrawal, GB‑115 increased striatal DOPAC levels.

    Peptide
    GB-115
    Outcome
    IncreaseStriatal DOPAC
    Study

    ratn: not reported in source

    Outbred rats during diazepam withdrawal
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1 and 0.5 mg/kg · intraperitonealAs given in this study (rat).

    Measurements

    DOPAC increase
    25%
    striatum

    Source sentences

    Summary
    In the striatum of outbred rats, GB-115 increased DOPAC (+25%) and DA (+31.6%) levels that were decreased during diazepam withdrawal syndrome.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In outbred rats during diazepam withdrawal, GB‑115 increased striatal DA levels by 31.6%.

    In plain wordsIn rats during diazepam withdrawal, GB‑115 increased striatal dopamine levels.

    Peptide
    GB-115
    Outcome
    IncreaseStriatal dopamine
    Study

    ratn: not reported in source

    Outbred rats during diazepam withdrawal
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    0.1 and 0.5 mg/kg · intraperitonealAs given in this study (rat).

    Measurements

    DA increase
    31.6%
    striatum

    Source sentences

    Summary
    In the striatum of outbred rats, GB-115 increased DOPAC (+25%) and DA (+31.6%) levels that were decreased during diazepam withdrawal syndrome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.